Medical Oncology Department, Centre Oscar Lambret, Lille, France.
Int J Oral Maxillofac Surg. 2011 Sep;40(9):938-42. doi: 10.1016/j.ijom.2010.11.028. Epub 2011 Apr 12.
The aim of this study is to analyse survival and prognostic factors in patients diagnosed with squamous cell carcinoma (SCC) presenting a first episode of cancer-associated hypercalcaemia (CAH). Retrospectively, the authors reviewed data from 220 patients with biopsy proven SCC who presented a first episode of CAH. They were treated in a single centre between 1995 and 2007. The survival analyses were done using the Kaplan-Meier method and Cox analysis. The primary endpoint was the overall survival from the date of hypercalcaemia episode. Median age was 55 years. Median survival was 64 days (1-197). Three independent prognostic factors were identified: brain metastasis (hazard ratio (HR)=2.58 CI (1.03-6.45)), corrected calcaemia>3 mmol/l (HR=1.45 CI (1.05-2.01)) and hypoalbuminaemia (HR=1.48 CI (1.07-2.04)). Using these factors, the authors performed a bedside prognostic score. In conclusion, median survival in patients diagnosed with SCC and CAH is extremely poor. The bedside prognostic score that the authors developed can help to anticipate patients' prognosis and adapt the treatment. This score needs to be validated on an independent cohort.
本研究旨在分析首次发生癌相关性高钙血症(CAH)的鳞状细胞癌(SCC)患者的生存和预后因素。回顾性分析了 1995 年至 2007 年间在一家中心接受治疗的 220 例经活检证实的 SCC 患者首次发生 CAH 的资料。生存分析采用 Kaplan-Meier 法和 Cox 分析。主要终点是从高钙血症发作日期开始的总生存。中位年龄为 55 岁。中位生存时间为 64 天(1-197)。确定了三个独立的预后因素:脑转移(风险比(HR)=2.58 CI(1.03-6.45))、校正血钙>3mmol/L(HR=1.45 CI(1.05-2.01))和低白蛋白血症(HR=1.48 CI(1.07-2.04))。作者使用这些因素进行了床边预后评分。结论:诊断为 SCC 和 CAH 的患者的中位生存时间极差。作者开发的床边预后评分有助于预测患者的预后并调整治疗。该评分需要在独立队列中进行验证。